Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 15, 2022 - Issue
Submit an article Journal homepage
165
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma

Saad AlShareef1 Department of Medicine, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317-4233, Saudi ArabiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0104-6583
ORCID Icon,
Christine F McDonald2 Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia;3 Institute for Breathing and Sleep, Heidelberg, Australia;4 Faculty of Medicine, University of Melbourne, Melbourne, Australia
&
Joy Lee2 Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Australia;5 School of Public Health & Preventive Medicine, Monash University, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0002-9881-9895
ORCID Icon
Pages 209-217 | Published online: 15 Feb 2022

References

  • Soriano JB, Abajobir AA, Abate KH; Collaborators GBDCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X
  • Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.00202013
  • Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3(1):1. doi:10.1186/s40733-016-0029-3
  • Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res. 2018;4(1):00125–2017. doi:10.1183/23120541.00125-2017
  • Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. Expert Opin Biol Ther. 2018;18(7):747–754. doi:10.1080/14712598.2018.1492540
  • Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med. 2014;20(1):87–94. doi:10.1097/MCP.0000000000000007
  • Roxas C, Fernandes M, Green L, et al. S80 A comparison of the clinical response to mepolizumab and benralizumab at 4 weeks. Thorax. 2018;73(Suppl4):A50. doi:10.1136/thorax-2018-212555.86
  • Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834. doi:10.1002/14651858.CD010834.pub3
  • Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;1:CD003559. doi:10.1002/14651858.CD003559.pub4
  • Cox L, Lieberman P, Wallace D, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol. 2011;128(1):210–212. doi:10.1016/j.jaci.2011.04.010
  • Liu T, Wang F, Wang G, Mao H. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials. Front Med. 2018;12(3):340–349. doi:10.1007/s11684-017-0565-0
  • Rogliani P, Calzetta L, Matera MG, et al. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2020;6(1):47–66. doi:10.1007/s41030-019-00109-1
  • Thompson CA, Eslick SR, Berthon BS, Wood LG. Asthma medication use in obese and healthy weight asthma: systematic review/meta-analysis. Eur Respir J. 2021;57(3):2000612. doi:10.1183/13993003.00612-2020
  • Leiria LO, Martins MA, Saad MJ. Obesity and asthma: beyond T(H)2 inflammation. Metabolism. 2015;64(2):172–181. doi:10.1016/j.metabol.2014.10.002
  • Makarova E, Ignatova G. Assessment of biological therapy in asthma-obesity phenotype. Eur Respir J. 2020;56(suppl 64):1408. doi:10.1183/13993003.congress-2020.1408
  • Albers FC, Papi A, Taille C, et al. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. Respir Res. 2019;20(1):169. doi:10.1186/s12931-019-1134-7
  • Akenroye A, Keet C. Underrepresentation of blacks, smokers, and obese patients in studies of monoclonal antibodies for asthma. J Allergy Clin Immunol Pract. 2020;8(2):739–741. doi:10.1016/j.jaip.2019.08.023
  • Kayser MZ, Drick N, Milger K, et al. Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months. J Asthma Allergy. 2021;14:863–871. doi:10.2147/JAA.S319572
  • Bourdin A, Husereau D, Molinari N, et al. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J. 2018;52(5):1801393. doi:10.1183/13993003.01393-2018
  • Cabon Y, Molinari N, Marin G, et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. 2017;47(1):129–138. doi:10.1111/cea.12853
  • Edris A, Lahousse L. Monoclonal antibodies in type 2 asthma: an updated network meta-analysis. Minerva Med. 2021;112(5). doi:10.23736/S0026-4806.21.07623-0
  • Busse W, Chupp G, Nagase H, et al. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200. doi:10.1016/j.jaci.2018.08.031
  • Becker AB, Abrams EM. Asthma guidelines: the Global Initiative for Asthma in relation to national guidelines. Curr Opin Allergy Clin Immunol. 2017;17(2):99–103. doi:10.1097/ACI.0000000000000346

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.